Evidence map›Paper›PMID 31244826›Full record

ArticleFrontiers in immunology2019

Interleukin-17D Promotes Pathogenicity During Infection by Suppressing CD8 T Cell Activity.

Younghee Lee, Jelita Clinton, Chengfang Yao, Seon Hee Chang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Spaceflight alters host-gut microbiota interactions.NPJ biofilms and microbiomes · 2024
    Article
  7. Interleukins in Epilepsy: Friend or Foe.Neuroscience bulletin · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Molecular Mechanisms of Hyperoxia-Induced Neonatal Intestinal Injury.International journal of molecular sciences · 2023
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Evaluation of IL-17D in Host Immunity to Group AJournal of immunology (Baltimore, Md. : 1950) · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Younghee LeeDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Jelita ClintonDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Chengfang YaoDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Seon Hee ChangDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Interleukin-17D (IL-17D) belongs to the IL-17 family of cytokines. While the members of the IL-17 family have been implicated in inflammation and host defense, the function of IL-17D remains unclear. Here, we showed that the lack of IL-17D expression confers protection against

Indexed as

ImmunomodulationAnimalsBiomarkersCD8-Positive T-LymphocytesDendritic CellsDisease Models, AnimalDisease SusceptibilityGene ExpressionImmunophenotypingImmunosuppression TherapyInfectionsInterleukin-17Lymphocyte ActivationMiceMice, TransgenicSeverity of Illness IndexBiomarkersInterleukin-17CD8dendritic cellsflu virusIL-17Dlisteria

Identifiers

PMID31244826
PMCPMC6562898
OpenAlexW2948552003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.